At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
PF-00299804drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1/2, OPEN-LABEL, SINGLE ARM TRIAL TO DETERMINE THE RECOMMENDED PHASE 2 DOSE AND EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS IN KOREA WITH KRAS WILD TYPE ADVANCED NSCLC, WHICH IS REFRACTORY TO CHEMOTHERAPY AND ERLOTINIB OR GEFITINIB
In Brief
A Phase 2 clinical trial evaluating PF-00299804 for Carcinoma, Non Small Cell Lung. Completed, enrolled 55 participants across 3 sites.
Detailed Summary
To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non Small Cell Lung
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartFeb 2008
Primary CompletionAug 2010
Study CompletionJul 2014
TodayJul 2026
First PostedNov 5, 2007
Enrollment StartFeb 5, 2008
Primary CompletionAug 3, 2010
Study CompletionJul 17, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.7 years ago
Interventions
PF-00299804drug
Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent